What Converge Bio does

Converge Bio is a privately held, venture-backed AI drug discovery company founded in 2024 and headquartered in Boston and Tel Aviv, with a Delaware-incorporated US entity (Converge Bio, Inc.) and an Israeli operating entity. The company builds a generative AI platform — branded as the Converge Computational Lab — composed of proprietary bio-LLM foundation models trained on the core biological languages of DNA, RNA, and protein sequences, and delivered as fully managed, dedicated private instances that can also be deployed on customer cloud infrastructure. Three flagship product modules share the underlying model library: ConvergeAB™ for antibody design and engineering (de novo design, affinity maturation, humanization, developability, and IP expansion across IgG, scFv, VHH, and bispecific formats); ConvergeGEO™ for gene expression and protein yield optimization across CHO, HEK293, E. coli, Pichia, S. cerevisiae, and A. oryzae; and ConvergeCELL™ for virtual cell, target, and biomarker discovery from single-cell and bulk transcriptomic data. A separate Converge-SC model handles single-cell RNA interpretation, and a free Patent Extractor tool supports antibody sequence extraction from patent documents.

The business model is enterprise SaaS delivered through a high-touch, expert-led sales motion targeting pharmaceutical and biotech customers. Pricing is not publicly disclosed; engagements are quote-based on multi-year contracts with customer-owned IP and dedicated isolated deployments. Converge reports 40+ completed programs for 12+ customers across the US, Canada, Europe, and Israel, with named logos including Purple Biotech, Compugen, and PreFer Industries. Revenue is supplemented by non-dilutive grant funding, most notably a $2.5M, 37-month Gates Foundation grant (June 2026) to extend the platform into crop genomics. As of the January 2026 Series A, the company had grown to roughly 34-40 employees, and has raised a total of $30M in equity across a $5.5M seed (TLV Partners, November 2024) and a $25M oversubscribed Series A (Bessemer Venture Partners lead, January 2026).

Name

Converge Bio

Legal name

Converge Bio, Inc.

Website

https://converge-bio.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

Converge Bio builds generative AI foundation models (bio-LLMs) for antibody design, protein expression optimization, and target/biomarker discovery, selling dedicated private instances on a multi-year enterprise basis to pharmaceutical and biotech customers across the US, Canada, Europe, and Israel.

Ownership category

akta.pro rank

Product category

AI Drug Discovery / Computational Biology Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• AI drug discovery
• Generative biology
• Antibody design platform
• Protein expression optimization
• Biomarker discovery

Headquarters

HQ city

Wilmington

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Enterprise SaaS / AI platform subscriptions and programs: Revenue generated from selling access to the Converge computational lab (ConvergeAB, ConvergeGEO, ConvergeCELL) deployed as dedicated private instances for pharma and biotech customers. Customers engage on a program basis for target discovery, antibody design, and protein manufacturing optimization. The company has completed over 40 programs with more than a dozen pharmaceutical and biotech customers.
2. Grant funding (non-dilutive): Non-dilutive grant funding from foundations and government-aligned programs; a $2.5M, 37-month grant from the Gates Foundation to extend the platform into crop genomics represents the first material example. Grant funding supplements platform and program revenue.
3. Professional / expert services bundled with platform access: Converge's GTM bundles its scientists and AI experts in a closed-loop partnership with customers, supporting design and discovery from setup through scaling. Expert support is part of the platform offering.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels11 records

Core offering

Converge Bio sells a Generative AI platform called the Converge Computational Lab, built on bio-LLMs trained on DNA, RNA, and protein sequences, and delivered to pharma and biotech customers as dedicated, private cloud instances. The platform comprises three flagship modules — ConvergeAB (antibody design), ConvergeGEO (gene expression / protein yield optimization), and ConvergeCELL (virtual cell and target/biomarker discovery) — supported by a free Converge Patent Extractor tool and the Converge-SC single-cell LLM. Customers engage on a multi-year program basis combining platform access with co-development by Converge's scientists and AI experts.

Product overview

Converge Bio offers a unified Generative AI platform for the life sciences, branded as the Converge Computational Lab, with three integrated product modules plus a free add-on tool. The platform is built on foundation models trained on the core biological languages of DNA, RNA, and protein sequences and is delivered as a managed, fully hosted service with private-by-design data isolation. The three core modules are: ConvergeAB™, an antibody design and engineering platform supporting de novo design, affinity maturation, humanization, and IP expansion; ConvergeGEO™, a generative protein yield optimization solution for CHO, HEK293, E. coli, Pichia, S. cerevisiae, and A. oryzae expression systems; and ConvergeCELL™, a virtual cell and precision medicine platform for biomarker and target discovery built on a patient-level single-cell foundation model. A separate large language model, Converge-SC, addresses single-cell RNA interpretation, and the free Converge Patent Extractor tool extracts structured antibody intelligence from patent filings. Together the products span target discovery, antibody design, protein manufacturing optimization, and biomarker discovery across the drug discovery life cycle.

Differentiator

Problem solved

Functional benefit

Brands

• ConvergeAB™: Generative AI platform for antibody design and engineering, supporting de novo design, affinity maturation, humanization, and developability optimization across IgG, VHH, scFv, and bispecific formats.
• ConvergeGEO™
• ConvergeCELL™
• Converge Patent Extractor

Products and services

• ConvergeAB™ Generative AI platform for antibody design and engineering, supporting de novo design, affinity maturation, humanization, and developability optimization across IgG, scFv, VHH, and bispecific formats. Trained on over 1 trillion natural protein tokens, 7M antibody sequences, 3M antibody-antigen pairs, and 10,000 developability measurements; generates ~100,000 target-aware candidates per campaign and filters them through orthogonal predictors for binding, stability, solubility, and structural fit. Sold to pharma and biotech R&D teams as part of the Converge Computational Lab.
• ConvergeGEO™ Generative AI yield optimization solution that designs host-specific DNA sequences (codons, UTRs, promoters, terminators) to maximize protein output across CHO, HEK293, E. coli, Pichia (K. phaffii), S. cerevisiae, and A. oryzae expression systems. Trained on 1+ trillion gene tokens and 100M+ expression profiles; benchmarked zero-shot to outperform GenScript, Twist, IDT, and ThermoFisher (p = 0.012) with customer-validated 4.5x–7x yield improvements. Sold to pharma and biotech manufacturing and process development teams.
• ConvergeCELL™ Patient-level single-cell and bulk transcriptomics foundation model for target and biomarker discovery, trained on 23M+ cells from 5,000 patient samples, 550 studies, and 40 clinical indications. Uses supervised contrastive learning to learn patient embeddings from single-cell data and knowledge distillation to extend the representation to bulk RNA-seq; includes a hypothesis-generation agent that connects an LLM to PubMed, Open Targets, and ClinicalTrials.gov to produce structured mechanism-of-action hypothesis cards. Validated zero-shot on SLE (AUROC 0.87), multiple myeloma (AUROC 0.72), and sepsis. Sold to pharma and biotech discovery and translational teams.
• Converge-SC Large language model that interprets single-cell RNA sequencing data, capable of processing over 20,000 genes per cell and trained on more than 36 million cells, supporting precision medicine and drug discovery through patient-level analysis. Deployed on Nebius infrastructure.
• Converge Patent Extractor Free online tool that extracts antibody-related information (sequences, CDRs, variants, targets, binding/affinity data) from US, EP, WO, and AU patent documents. Reads ST.26 XML, ST.25 listings, pre-ST.25 prose, FASTA dumps, and scanned PDFs via vision OCR; benchmarked at 98% agreement with PLAbDab on 500+ patents and 2.8x more antibodies recovered. Offered free with a per-email submission cap to computational biologists and antibody discovery scientists.

Quantifiable outcome

• 4.5x protein yield increase for PreFer Industries using the same production system
• +7 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability11 records

Feature7 records

Partnerships

Seven partnerships are on record, tiered flagship / first major grant partner and agricultural expansion anchor, core / strategic oncology collaboration, core / ai compute infrastructure partner, minor / early collaboration, flagship / accelerator partner with co-marketing and cloud credits and core / open-source distribution and research community channel.

• Gates Foundationflagship / first major grant partner and agricultural expansion anchorStrategic or Co-development Partner · 1 June 2026Awarded Converge Bio a $2.5M, 37-month grant in June 2026 to extend its generative AI platform from pharmaceutical research into agricultural biotechnology, specifically crop genomics. The initiative develops a multimodal foundation model to identify genetic variants linked to yield and climate resilience, supporting the Gates Foundation's goal of helping smallholder farmers in sub-Saharan Africa and South Asia adapt to climate volatility.
• Purple Biotech (expanded collaboration)core / strategic oncology collaborationStrategic or Co-development Partner · 1 May 2026Expanded its collaboration with Converge Bio to apply generative AI to antibody design and established a Scientific Advisory Board to support the CAPTN-3 platform development toward first-in-human studies in 2027, as part of Purple Biotech's Q1 2026 results announcement.
• Purple Biotechcore / strategic oncology collaborationStrategic or Co-development Partner · 25 March 2026Collaboration announced March 25, 2026 to leverage Converge Bio's generative AI to accelerate development of Purple Biotech's CAPTN-3 tri-specific antibody platform targeting solid tumors. The AI-driven approach is designed to reduce discovery timelines, improve candidate quality, and expand the CAPTN-3 platform to additional high-value oncology targets and resistance mechanisms, including T cell engagers and NK cell engagers.
• Nebiuscore / ai compute infrastructure partnerTechnology or Integration · 1 May 2025Converge Bio is using Nebius AI cloud infrastructure to support single-cell research and precision-medicine workloads, including the Converge-SC model. Highlighted as a partner case study in Nebius's monthly digest in May 2025.
• Compugenminor / early collaborationStrategic or Co-development Partner · 1 September 2024Announced an 'Exciting Collaboration' with Converge Bio in September 2024, referenced on Converge Bio's news page as an early antibody design collaboration.
• Amazon Web Services (AWS)flagship / accelerator partner with co-marketing and cloud creditsGTM or Marketing Partner · 1 September 2024Converge Bio was selected to participate in the 2024 AWS Generative AI Accelerator program, an $230M AWS initiative promoting generative AI applications. Converge Bio received mentorship, funding, and go-to-market support, and was part of an 80-startup cohort from 129 countries receiving up to $1M in AWS credits.
• Hugging Facecore / open-source distribution and research community channelOEM/ Whitelabel/ Licensing PartnerConvergeCELL's patient representation engine is published open source on Hugging Face (huggingface.co/ConvergeBio) to empower the research community and build Converge Bio's developer/credential footprint.

Scale indicators16 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• EvolutionaryScale: EvolutionaryScale is a research-driven AI company building large biological foundation models (ESM family) for protein design and therapeutic discovery. It overlaps with Converge's protein-language-model approach but is focused on general-purpose foundation models rather than full-stack pharma delivery.
• Profluent Bio: Profluent Bio builds AI foundation models for protein design, including antibodies. It is an emerging competitor in AI-driven protein engineering with overlapping capabilities to ConvergeAB but operates at a more research-focused stage.

Direct peers

• Generate Biomedicines: Generate Biomedicines is a generative biology company building foundation models to design novel protein therapeutics. It directly competes with ConvergeAB in AI-driven antibody and protein design and shares the same foundation-model architecture philosophy.
• BigHat Biosciences: BigHat Biosciences combines generative AI with wet-lab experimentation to design antibody therapeutics. It competes directly with ConvergeAB's de novo design, affinity maturation, and developability optimization capabilities.
• Cradle Bio: Cradle is a generative AI protein design platform focused on engineering biologics including antibodies and enzymes. Converge explicitly benchmarks against Cradle (4.4x stronger binding than a Cradle-derived competitor), and the two compete head-to-head in AI-driven antibody and protein design for pharma.
• Insitro: Insitro is a machine learning-driven drug discovery company combining high-throughput biology with ML models to discover therapeutics. It overlaps directly with ConvergeCELL's target/biomarker discovery mission and competes for the same large-pharma partnerships.

Broad incumbents

• Absci: Absci is a generative AI drug creation company combining generative AI with a proprietary wet-lab platform for antibody discovery and design. As a public company with established pharma partnerships, it is an incumbent competitor to ConvergeAB.
• Recursion Pharmaceuticals: Recursion is an established clinical-stage TechBio combining high-throughput experimental biology with AI/ML for drug discovery. As a public incumbent with multiple partnerships and programs, it represents a broader competitor in the AI-driven pharma discovery space.
• Isomorphic Labs: Isomorphic Labs is Alphabet's commercial AI drug discovery subsidiary spun out of DeepMind's AlphaFold work. It operates broadly across the same AI-driven therapeutic discovery space as Converge and represents a well-capitalized incumbent with deep-pocketed Big Tech backing.
• AbCellera: AbCellera is a clinical-stage biotech that combines a proprietary antibody discovery platform with internal development programs. It is an established incumbent in AI-augmented antibody discovery and overlaps with ConvergeAB's antibody design capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/converge-bio

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Converge Bio